Statin RCT meta-analyses show no increase or decrease in cancer risk
Louis compiles meta-analyses of randomized trials showing statins neither raise nor lower cancer incidence or mortality, plus cohort studies suggesting neutral or lower cancer risk, e.g. prostate cancer. He adds that RCTs and prospective cohorts sit at the top of the evidence hierarchy.












